{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T04:45:13Z","timestamp":1773549913743,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T00:00:00Z","timestamp":1407974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00415-014-7462-0","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T18:04:48Z","timestamp":1408557888000},"page":"516-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"262","author":[{"given":"Daniel","family":"Caldeira","sequence":"first","affiliation":[]},{"given":"M\u00e1rcio","family":"Barra","sequence":"additional","affiliation":[]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,8,14]]},"reference":[{"key":"7462_CR1","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00228-013-1510-z","volume":"69","author":"S Harder","year":"2013","unstructured":"Harder S, Graff J (2013) Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 69:1617\u20131633","journal-title":"Eur J Clin Pharmacol"},{"key":"7462_CR2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","volume":"95","author":"CS Landefeld","year":"1993","unstructured":"Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95:315\u2013328","journal-title":"Am J Med"},{"key":"7462_CR3","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/j.1538-7836.2010.04016.x","volume":"8","author":"L Linkins","year":"2010","unstructured":"Linkins L, O\u2019Donnell M, Julian JA, Kearon C (2010) Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost 8:2201\u20132207","journal-title":"J Thromb Haemost"},{"key":"7462_CR4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","volume":"120","author":"MC Fang","year":"2007","unstructured":"Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG et al (2007) Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120:700\u2013705","journal-title":"Am J Med"},{"key":"7462_CR5","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.amjcard.2013.11.049","volume":"113","author":"BJ Bloom","year":"2014","unstructured":"Bloom BJ, Filion KB, Atallah R, Eisenberg MJ (2014) Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. Am J Cardiol 113:1066\u20131074","journal-title":"Am J Cardiol"},{"key":"7462_CR6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amjcard.2013.03.054","volume":"112","author":"G Wasserlauf","year":"2013","unstructured":"Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ (2013) Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol 112:454\u2013460","journal-title":"Am J Cardiol"},{"key":"7462_CR7","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"7462_CR8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0962280211432218","volume":"22","author":"PW Lane","year":"2013","unstructured":"Lane PW (2013) Meta-analysis of incidence of rare events. Stat Methods Med Res 22:117\u2013132","journal-title":"Stat Methods Med Res"},{"key":"7462_CR9","doi-asserted-by":"crossref","first-page":"e59202","DOI":"10.1371\/journal.pone.0059202","volume":"8","author":"RM Turner","year":"2013","unstructured":"Turner RM, Bird SM, Higgins JP (2013) The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One 8:e59202","journal-title":"PLoS One"},{"key":"7462_CR10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982\u2013989","journal-title":"Ann Intern Med"},{"key":"7462_CR11","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/cc11919","volume":"17","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Xu X, Ni H (2013) Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care 17:R2","journal-title":"Crit Care"},{"key":"7462_CR12","unstructured":"Higgins JPT, Altman DG, Sterne JAC (2011). Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http:\/\/www.cochrane-handbook.org"},{"key":"7462_CR13","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","volume":"21","author":"JJ Deeks","year":"2002","unstructured":"Deeks JJ (2002) Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 21:1575\u20131600","journal-title":"Stat Med"},{"key":"7462_CR14","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","volume":"318","author":"L Smeeth","year":"1999","unstructured":"Smeeth L, Haines A, Ebrahim S (1999) Numbers needed to treat derived from meta-analyses\u2014sometimes informative, usually misleading. BMJ 318:1548\u20131551","journal-title":"BMJ"},{"key":"7462_CR15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/ebn.4.2.36","volume":"4","author":"A DiCenso","year":"2001","unstructured":"DiCenso A (2001) Clinically useful measures of the effects of treatment. Evid Based Nurs. 4:36\u201339","journal-title":"Evid Based Nurs."},{"key":"7462_CR16","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2011) Chapter 9: analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http:\/\/www.cochrane-handbook.org"},{"key":"7462_CR17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"7462_CR18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","volume":"295","author":"JL Peters","year":"2006","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676\u2013680","journal-title":"JAMA"},{"key":"7462_CR19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594\u2013604","journal-title":"N Engl J Med"},{"key":"7462_CR20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699\u2013708","journal-title":"N Engl J Med"},{"key":"7462_CR21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806\u2013817","journal-title":"N Engl J Med"},{"key":"7462_CR22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"7462_CR23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799\u2013808","journal-title":"N Engl J Med"},{"key":"7462_CR24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368:699\u2013708","journal-title":"N Engl J Med"},{"key":"7462_CR25","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","volume":"365","author":"SZ Goldhaber","year":"2011","unstructured":"Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167\u20132177","journal-title":"N Engl J Med"},{"key":"7462_CR26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"7462_CR27","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342\u20132352","journal-title":"N Engl J Med"},{"key":"7462_CR28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709\u2013718","journal-title":"N Engl J Med"},{"key":"7462_CR29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, Hokusai-VTE Investigators et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415","journal-title":"N Engl J Med"},{"key":"7462_CR30","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"7462_CR31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673\u20131680","journal-title":"Lancet"},{"key":"7462_CR32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"issue":"2104","key":"7462_CR33","first-page":"11","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S et al (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study. Circ J 76(2104):11","journal-title":"Circ J"},{"key":"7462_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9\u201319","journal-title":"N Engl J Med"},{"key":"7462_CR35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"B\u00fcller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, EINSTEIN\u2013PE Investigators et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 366:1287\u20131297","journal-title":"N Engl J Med."},{"key":"7462_CR36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","volume":"368","author":"AT Cohen","year":"2013","unstructured":"Cohen AT, Spiro TE, B\u00fcller HR, Haskell L, Hu D, Hull R et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513\u2013523","journal-title":"N Engl J Med"},{"key":"7462_CR37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1474-4422(07)70107-2","volume":"6","author":"CE Lovelock","year":"2007","unstructured":"Lovelock CE, Molyneux AJ, Rothwell PM, Oxford Vascular Study (2007) Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol 6:487\u2013493","journal-title":"Lancet Neurol"},{"key":"7462_CR38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/bmj.318.7186.759","volume":"318","author":"AG Thrift","year":"1999","unstructured":"Thrift AG, McNeil JJ, Forbes A, Donnan GA (1999) Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case\u2013control study. BMJ 318:759\u2013764","journal-title":"BMJ"},{"key":"7462_CR39","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/j.1538-7836.2010.04016.x","volume":"8","author":"L Linkins","year":"2010","unstructured":"Linkins L, O\u2019Donnell M, Julian JA, Kearon C (2010) Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost 8:2201\u20132207","journal-title":"J Thromb Haemost"},{"key":"7462_CR40","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","volume":"43","author":"RG Hart","year":"2012","unstructured":"Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA et al (2012) Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43:1511\u20131517","journal-title":"Stroke"},{"key":"7462_CR41","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ, Stevens SR, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL et al (2014) Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 45:1304\u20131312","journal-title":"Stroke"},{"key":"7462_CR42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3111\/13696998.2012.680555","volume":"15","author":"S Deitelzweig","year":"2012","unstructured":"Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J et al (2012) Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 15:776\u2013785","journal-title":"J Med Econ"},{"key":"7462_CR43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCOUTCOMES.113.000661","volume":"6","author":"WJ Canestaro","year":"2013","unstructured":"Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA et al (2013) Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes 6:724\u2013731","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"7462_CR44","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/phar.1269","volume":"33","author":"M Mahmoudi","year":"2013","unstructured":"Mahmoudi M, Sobieraj DM (2013) The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. Pharmacotherapy 33:1333\u20131340","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-014-7462-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7462-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T04:31:14Z","timestamp":1565757074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-014-7462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,14]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["7462"],"URL":"https:\/\/doi.org\/10.1007\/s00415-014-7462-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,14]]}}}